Affiliation: University of Rochester
- A robust method using propensity score stratification for correcting verification bias for binary testsHua He
Department of Biostatistics and Computational Biology, University of Rochester, Rochester, NY 14642, USA
Biostatistics 13:32-47. 2012....
- Design and analysis of two-period studies of potentially disease-modifying treatmentsMichael P McDermott
Department of Biostatistics, University of Rochester, Rochester, NY 14642, USA
Control Clin Trials 23:635-49. 2002..Advantages and limitations of the various designs are discussed...
- Needed in MS: evidence, not EVIDENCEKarl Kieburtz
Department of Neurology, University of Rochester Medical Center, NY 14642, USA
Neurology 59:1482-3. 2002
- Effects of gabapentin on sleep in menopausal women with hot flashes as measured by a Pittsburgh Sleep Quality Index factor scoring modelMichael E Yurcheshen
Department of Neurology, University of Rochester School of Medicine and Dentistry, Strong Sleep Disorders Center, Rochester, New York 14618, USA
J Womens Health (Larchmt) 18:1355-60. 2009..The aim of this research was to analyze gabapentin's effect on Pittsburgh Sleep Quality Index (PSQI) scores in menopausal women...
- Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trialRobert G Holloway
Department of Neurology, University of Rochester, 1351 Mt Hope Avenue, Suite 220, Rochester, NY 14620, USA
Arch Neurol 61:1044-53. 2004..The best way to initiate dopaminergic therapy for early Parkinson disease remains unclear...
- Predictors of deterioration in health-related quality of life in Parkinson's disease: results from the DATATOP trialConnie Marras
Division of Neurology, Toronto Western Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada
Mov Disord 23:653-9; quiz 776. 2008..Our focus in clinical care needs to be broadened beyond assessing and treating Parkinsonism, recognizing the impact of mood, cognition and function on HRQOL...
- Less is more, or almost as much: a 15-item quality-of-life instrument for myasthenia gravisTed M Burns
Department of Neurology, University of Virginia, Charlottesville, PO Box 800394, Charlottesville, Virginia 22908, USA
Muscle Nerve 38:957-63. 2008..Because the MG-QOL15 instrument can be quickly and easily administered and interpreted, it is a potential QOL measure for treatment trials and the clinical evaluation of patients with MG...
- Disease-specific measure of quality of life for myasthenia gravisLarry L Mullins
University of Oklahoma Health Sciences Center, Department of Pediatrics, Oklahoma City, Oklahoma, USA
Muscle Nerve 38:947-56. 2008..Results from this study support the use of this new measure of QOL, both clinically and in treatment trials of MG...
- Neuroradiographic changes following convection-enhanced delivery of the recombinant cytotoxin interleukin 13-PE38QQR for recurrent malignant gliomaIan F Parney
Department of Neurological Surgery, Brain Tumor Research Center, University of California at San Francisco, California 94143 0350, USA
J Neurosurg 102:267-75. 2005..Serial neuroradiographic changes were assessed in this cohort of patients...
- Perioperative complications and neurological outcomes of first and second craniotomies among patients enrolled in the Glioma Outcome ProjectSusan M Chang
Brain Tumor Research Center, Department of Neurological Surgery, University of California, San Francisco, California 94143 0372, USA
J Neurosurg 98:1175-81. 2003..Factors predicting neurological outcome would also be helpful for patient selection for surgically based clinical trials...
- Test-retest reliability of the unified Parkinson's disease rating scale in patients with early Parkinson's disease: results from a multicenter clinical trialAndrew Siderowf
Department of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania, USA
Mov Disord 17:758-63. 2002..The findings are in agreement with previous reports on interrater reliability...